Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 344 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German sold 344 shares of the business’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $54.23, for a total transaction of $18,655.12. Following the transaction, the chief accounting officer now owns 2,889 shares in the company, valued at approximately $156,670.47. This represents a 10.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christopher Paul German also recently made the following trade(s):

• On Wednesday, February 19th, Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock. The shares were sold at an average price of $57.22, for a total value of $36,334.70.

Rhythm Pharmaceuticals Trading Up 2.6 %

NASDAQ RYTM opened at $54.30 on Thursday. The firm’s fifty day moving average price is $55.26 and its two-hundred day moving average price is $55.02. The firm has a market capitalization of $3.43 billion, a P/E ratio of -12.54 and a beta of 2.30. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. On average, research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on RYTM shares. Needham & Company LLC lifted their target price on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. Stifel Nicolaus began coverage on Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They set a “buy” rating and a $78.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Jefferies Financial Group assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $69.46.

Institutional Trading of Rhythm Pharmaceuticals

Several large investors have recently made changes to their positions in RYTM. Victory Capital Management Inc. raised its holdings in Rhythm Pharmaceuticals by 158.0% in the 3rd quarter. Victory Capital Management Inc. now owns 18,186 shares of the company’s stock valued at $953,000 after buying an additional 11,137 shares during the last quarter. Quest Partners LLC grew its holdings in Rhythm Pharmaceuticals by 451.6% in the third quarter. Quest Partners LLC now owns 9,167 shares of the company’s stock worth $480,000 after purchasing an additional 7,505 shares during the period. Intech Investment Management LLC bought a new stake in Rhythm Pharmaceuticals in the third quarter valued at $649,000. Charles Schwab Investment Management Inc. raised its stake in Rhythm Pharmaceuticals by 1.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,866 shares of the company’s stock worth $22,730,000 after buying an additional 5,908 shares during the period. Finally, Penserra Capital Management LLC acquired a new stake in Rhythm Pharmaceuticals in the third quarter valued at approximately $1,313,000.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.